Godavari Drugs Limited (BOM:530317)
103.95
-1.05 (-1.00%)
At close: Aug 17, 2026
Godavari Drugs Revenue
Godavari Drugs had revenue of 281.08M INR in the quarter ending June 30, 2026, with 17.99% growth. This brings the company's revenue in the last twelve months to 1.11B, up 5.44% year-over-year. In the fiscal year ending March 31, 2026, Godavari Drugs had annual revenue of 1.07B, down -6.57%.
Revenue (ttm)
1.11B
Revenue Growth
+5.44%
P/S Ratio
0.71
Revenue / Employee
10.46M
Employees
106
Market Cap
782.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.07B | -74.92M | -6.57% |
| Mar 31, 2025 | 1.14B | -431.17M | -27.42% |
| Mar 31, 2024 | 1.57B | -24.03M | -1.51% |
| Mar 31, 2023 | 1.60B | -16.37M | -1.01% |
| Mar 31, 2022 | 1.61B | 384.48M | 31.31% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aayush Wellness | 1.66B |
| Makers Laboratories | 1.49B |
| Concord Drugs | 860.69M |
| Source Natural Foods and Herbal Supplements | 796.24M |
| Mercury Laboratories | 737.65M |
| Onyx Biotec | 694.69M |
| Amwill Health Care | 454.92M |
| Biofil Chemicals and Pharmaceuticals | 346.26M |